bluebird bio (BLUE) News Today $3.79 +0.04 (+1.07%) Closing price 04:00 PM EasternExtended Trading$3.67 -0.12 (-3.17%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period bluebird bio (BLUE) Expected to Announce Earnings on MondayMarch 22, 2025 | americanbankingnews.comGene therapy loses luster as investors eye quicker returns from weight-loss drugsMarch 21, 2025 | msn.comIn the Thymus We Trust: ProTcell Therapy & the Future of Allogeneic ImmunotherapyMarch 18, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUEMarch 17, 2025 | prnewswire.comMan Cured Of Sickle Cell Disease In New York Thanks To New Gene TherapyMarch 15, 2025 | forbes.comBristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio In $286M DealMarch 12, 2025 | msn.comBristol-Myers Squibb To Acquire 2seventy bio - A Sad But Inevitable End To A Cell Therapy PioneerMarch 12, 2025 | seekingalpha.comBristol Myers acquires cell therapy partner 2seventy bio for about $286 millionMarch 11, 2025 | msn.com2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300MMarch 11, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUEMarch 11, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUEMarch 3, 2025 | prnewswire.comBluebird Bio upgraded to Neutral from Underweight at JPMorganFebruary 24, 2025 | markets.businessinsider.comBluebird Bio price target lowered to $5 from $40 at Wells FargoFebruary 24, 2025 | markets.businessinsider.comBluebird bio stock slides for second day on buyout newsFebruary 24, 2025 | msn.comBLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUEFebruary 24, 2025 | businesswire.comOnce a darling of biotech, bluebird sells for less than $30M upfrontFebruary 23, 2025 | bizjournals.comBluebird Bio to Be Acquired by Carlyle Group, SK CapitalFebruary 21, 2025 | msn.comBluebird Bio trading halted, volatility trading pauseFebruary 21, 2025 | markets.businessinsider.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc.February 21, 2025 | prnewswire.comOnce high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy makerFebruary 21, 2025 | cnbc.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of bluebird bio, Inc. - BLUEFebruary 21, 2025 | prnewswire.comShareholder Alert: Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for its Public ShareholdersFebruary 21, 2025 | businesswire.comBLUE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of bluebird bio, Inc. Is Fair to ShareholdersFebruary 21, 2025 | businesswire.combluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK CapitalFebruary 21, 2025 | businesswire.comHigh-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment modelsFebruary 18, 2025 | cnbc.combluebird bio (NASDAQ:BLUE) Stock Price Passes Below Two Hundred Day Moving Average - Should You Sell?bluebird bio (NASDAQ:BLUE) Stock Passes Below 200-Day Moving Average - Here's What HappenedFebruary 14, 2025 | marketbeat.combluebird bio, Inc. (NASDAQ:BLUE) Given Consensus Rating of "Hold" by BrokeragesShares of bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) have been assigned an average rating of "Hold" from the nine analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and two have giFebruary 6, 2025 | marketbeat.comBluebird bio chief business officer Joseph Vittiglio sells $1,759 in stockFebruary 5, 2025 | msn.comBluebird bio's chief commercial officer Klima sells $901 in stockFebruary 5, 2025 | msn.comShort Interest in bluebird bio, Inc. (NASDAQ:BLUE) Drops By 6.6%bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) was the recipient of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 2,410,000 shares, a drop of 6.6% from the December 31st total of 2,580,000 shares. Currently, 25.0% of the shares of the company are sold short. Based on an average daily volume of 405,100 shares, the short-interest ratio is presently 5.9 days.February 3, 2025 | marketbeat.combluebird bio (NASDAQ:BLUE) Share Price Passes Below 200 Day Moving Average - Here's What Happenedbluebird bio (NASDAQ:BLUE) Stock Passes Below 200-Day Moving Average - Time to Sell?February 1, 2025 | marketbeat.comQ4 EPS Estimates for bluebird bio Increased by Analystbluebird bio, Inc. (NASDAQ:BLUE - Free Report) - Research analysts at Leerink Partnrs increased their Q4 2024 EPS estimates for shares of bluebird bio in a research note issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will post earJanuary 24, 2025 | marketbeat.comCantor Fitzgerald Weighs in on bluebird bio FY2025 Earningsbluebird bio, Inc. (NASDAQ:BLUE - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for bluebird bio in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the biotechnology company will earn ($23January 23, 2025 | marketbeat.comCantor Fitzgerald Forecasts bluebird bio FY2025 Earningsbluebird bio, Inc. (NASDAQ:BLUE - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of bluebird bio in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the biotechnology compaJanuary 22, 2025 | marketbeat.combluebird bio, Inc. (NASDAQ:BLUE) Short Interest Updatebluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) was the recipient of a large decrease in short interest in December. As of December 31st, there was short interest totalling 2,410,000 shares, a decrease of 6.6% from the December 15th total of 2,580,000 shares. Currently, 25.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 405,100 shares, the short-interest ratio is presently 5.9 days.January 18, 2025 | marketbeat.com'Will it really work?': Young sickle cell patient among the first to start new gene therapyJanuary 18, 2025 | msn.combluebird bio, Inc. (NASDAQ:BLUE) Given Consensus Rating of "Hold" by AnalystsShares of bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) have been assigned a consensus rating of "Hold" from the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recomJanuary 12, 2025 | marketbeat.comNational Resilience to lay off 120 in North CarolinaJanuary 9, 2025 | finance.yahoo.combluebird bio (NASDAQ:BLUE) Stock Price Passes Below 200-Day Moving Average - Here's Whybluebird bio (NASDAQ:BLUE) Stock Passes Below 200-Day Moving Average - Here's What HappenedJanuary 8, 2025 | marketbeat.comBiotech manufacturer plans to cut 120 jobs in DurhamJanuary 7, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Cencora (COR) and Bluebird Bio (BLUE)January 7, 2025 | markets.businessinsider.comBluebird Bio price target lowered to $8 at RBC Capital on ‘limited cash runway’January 7, 2025 | markets.businessinsider.comBluebird Bio price target adjusted for stock split at BarclaysDecember 31, 2024 | markets.businessinsider.combluebird bio (NASDAQ:BLUE) Price Target Raised to $40.00 at BarclaysBarclays increased their price target on shares of bluebird bio from $2.00 to $40.00 and gave the company an "overweight" rating in a research note on Tuesday.December 31, 2024 | marketbeat.comBluebird Bio’s Strategic Restructuring and Valuation Uplift Justifies Buy RatingDecember 31, 2024 | markets.businessinsider.comBluebird Bio’s Strategic Restructuring and Valuation Uplift Justifies Buy RatingDecember 31, 2024 | markets.businessinsider.combluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now?December 29, 2024 | insidermonkey.combluebird bio, Inc. (NASDAQ:BLUE) Sees Significant Decrease in Short Interestbluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) saw a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 2,580,000 shares, a drop of 94.8% from the November 30th total of 49,570,000 shares. Currently, 26.8% of the company's shares are sold short. Based on an average daily volume of 418,200 shares, the days-to-cover ratio is currently 6.2 days.December 26, 2024 | marketbeat.com2seventy bio: All In On Abecma Multiple Myeloma TreatmentDecember 23, 2024 | seekingalpha.comStockNews.com Initiates Coverage on bluebird bio (NASDAQ:BLUE)StockNews.com started coverage on bluebird bio in a research report on Friday. They issued a "sell" rating on the stock.December 20, 2024 | marketbeat.com Remove Ads Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address BLUE Media Mentions By Week BLUE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLUE News Sentiment▼0.430.78▲Average Medical News Sentiment BLUE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLUE Articles This Week▼35▲BLUE Articles Average Week Remove Ads Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TuHURA Biosciences News Today Greenwich LifeSciences News Today Larimar Therapeutics News Today Compugen News Today Zentalis Pharmaceuticals News Today Actuate Therapeutics News Today Organigram News Today Journey Medical News Today Alector News Today Cassava Sciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BLUE) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bluebird bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BLUE Stock Free BLUE Stock Alerts